Judge Madeline Cox Arleo oversees the Newark hearing, which clears the way for a massive $7.4 billion settlement plan.
The company admitted to deceiving regulators and paying doctor kickbacks to aggressively drive sales of its powerful painkiller, OxyContin.
This final criminal sentence allows the firm to dissolve and reorganize into a public benefit company called Knoa Pharma.
The new entity will focus on producing addiction treatments and overdose reversal medicines to support impacted communities nationwide.
Most of the multi-billion dollar settlement funds addiction prevention programs across state, local, and Native American tribal governments.
A specific $865 million fund provides direct compensation to individuals and families who suffered through the addiction crisis.
Victims recently testified about their losses, urging the court to remember the human cost behind these corporate legalities.
Purdue remains on track to emerge from bankruptcy by May 1, officially ending its previous commercial operations forever.
